ReWind Therapeutics SA
4.9 FTEReWind Therapeutics reported total assets of €2.09m at the end of the 2025 financial year (annual accounts filed with the NBB on 08 Jul 2026), with 4.9 full-time equivalents.
By total assets for 2025, ReWind Therapeutics ranks in the top half of the 993 companies in its sector (NACE 7210) in Belgium that filed accounts for that financial year. Largest companies in the sector →
The score of ReWind Therapeutics shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Total assets -66 % Headcount (avg FTE) -36 %
Accounts of the company itself (not consolidated).
The full file covers 8 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
ReWind Therapeutics's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 08 Jul 2026
- Year ended 31 Dec 2024filed on 26 May 2025
- Year ended 31 Dec 2023filed on 17 May 2024
- Year ended 31 Dec 2022filed on 31 May 2023
- Year ended 31 Dec 2021filed on 30 Jun 2022
ReWind Therapeutics's financial analysis
- Solvency-124.5%sector median: 60.4%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of ReWind Therapeutics
ReWind Therapeutics's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0682.626.216
- VAT number
- BE0682626216
- Peppol
- Registered · 0208:0682626216 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 06 Oct 2017
- Registered office
- 3001 Leuven
- Size
- Micro · 4.9 FTE
- Latest accounts
- 2025 · filed on 08 Jul 2026
- Activity
- Research and experimental development on biotechnology (NACE 72101)
ReWind Therapeutics (SA) has been based in Leuven since 2017, active in: research and experimental development on biotechnology. For 2025, it reports a net loss of €4.64m and equity of −€2.60m; its revenue is not published. With 4.9 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at -124.5%, below the median of its sector (60.4%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to ReWind Therapeutics
Companies in the same business, of comparable size and area, outside its group.
- NanoBiotech Research and experimental development on natural sciences and engineering Diepenbeek · balance sheet 1,834 €
- Apotheker-Bioloog Dimitri Baetens Research and experimental development on natural sciences and engineering Lokeren · balance sheet €2.15m
- Sunrock Assets Belgium I Research and experimental development on natural sciences and engineering Brussels · balance sheet €2.21m
- NewMilkLab Research and experimental development on natural sciences and engineering Ghent · balance sheet €2.32m
- Otorino Research and experimental development on natural sciences and engineering Waterloo · balance sheet €1.86m
- E-Proteins Research and experimental development on natural sciences and engineering Gembloux · balance sheet €1.71m
- Dr. G. Degraeve, Psychiater Research and experimental development on natural sciences and engineering Maldegem · balance sheet €2.56m
- Matthys Charlotte Research and experimental development on natural sciences and engineering Aalter · balance sheet €1.65m
Frequently asked questions about ReWind Therapeutics
What is the revenue of ReWind Therapeutics?
ReWind Therapeutics files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of ReWind Therapeutics?
In Belgium, the VAT number is the company number prefixed with BE: BE0682626216 for ReWind Therapeutics, if the company is VAT-registered. Its company number (CBE) is 0682.626.216.
Where is the registered office of ReWind Therapeutics?
According to the CBE register, the registered office of ReWind Therapeutics is in 3001 Leuven.
What is the equity of ReWind Therapeutics?
At the close of the 2025 financial year, the equity of ReWind Therapeutics amounts to -2,602,188 €, a solvency of -124.5% of total assets.
How many people work at ReWind Therapeutics?
4.9 full-time equivalents on average according to the 2025 social balance sheet.
Who manages ReWind Therapeutics?
The register lists 11 active mandates at ReWind Therapeutics. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
How large is ReWind Therapeutics within its sector?
By total assets for 2025, ReWind Therapeutics ranks in the top half of the 993 companies in its sector (NACE 7210) in Belgium that filed accounts for that financial year.
The full file of ReWind Therapeutics
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →